| Revenue growth | FY26 revenue up 17% YoY to ₹14,278 Cr. |
|---|---|
| Margins | Adj. EBITDA margin at 27.1% for Q4FY26; 25.4% for FY26. |
| Demand visibility | High in chronic therapies like Cardiac (14.7%) and Anti-Diabetes (11.6%). |
| Management confidence | Strong confidence in domestic chronic and specialty growth pillars. |
Growth
FY26 revenue grew 17.0% YoY; EBITDA increased 15.5%. Q4FY26 revenue up 11.8% YoY.
Outlook
Targeting deeper CVM penetration (72% by FY26) and inorganic growth through super-specialty M&A.
Risks
International business faced headwinds from geo-political issues; anti-infectives segment saw muted growth.
Earnings Call filed with BSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,500.00
- Market cap
- ₹1,03,261 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.5×Sector 47.3×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Employee Stock Options
Mankind Pharma has allotted 49,112 equity shares under its ESOP Plan 2022 to eligible employees upon exercise of options. The allotment increases its paid-up share capital.
- Value
- ₹4.22 Cr
Mankind Pharma Employee Stock Options
Mankind Pharma has allotted 49,112 equity shares under its ESOP scheme. This allotment increases the paid-up share capital by Rs. 49,112 in face value.
Mankind Pharma Management Change
Mankind Pharma announced the cessation of Mr. Bharat Anand as an Independent Director, effective August 30, 2026, upon the completion of his second term.